This covers the Marburg Virus Real Time PCR Kit. This kit is used for the detection of ribonucleic acid from the Marburg Virus. It’s an in-vitro diagnostic test that makes use of real-time PCR technology.
Virax Biolabs notes that the Marburg Virus is highly virulent and causes hemorrhagic fever. The severity of the disease means that there’s significant demand for accurate test kits. This has the company planning to distribute the kits in areas where CE marking is accepted.
James Foster, Chairman and CEO of Virax Biolabs, said the following about the news boosting VRAX stock today:
“We are committed to developing and distributing innovative diagnostic tools to combat infectious diseases. Our Marburg Virus PCR testing kit is a significant step forward in our mission to improve global health.”
What This Means for VRAX Stock
A distribution agreement is a win for investors in VRAX stock and it secures future sales. This has investors buying up shares today with some 10.3 million units on the move as of this writing. For comparison, the company’s daily average trading volume is closer to 1.4 million shares.
VRAX stock is up 14.2% as of Wednesday morning.
Investors looking for more of the most recent stock market news will want to keep reading!
InvestorPlace is home to all of the latest stock market news traders need to know about on Wednesday. A few examples include why shares of Intuitive Machines (NASDAQ:LUNR), Gamida Cell (NASDAQ:GMDA) and Allarity Therapeutics (NASDAQ:ALLR) stock are moving today. You can catch up on all of that news at the following links!
More Wednesday Stock Market News
- LUNR Stock Alert: The $719 Million Reason Intuitive Machines Is Rising Today
- Why Is Gamida Cell (GMDA) Stock Down 19% Today?
- Why Is Allarity Therapeutics (ALLR) Stock Down 22% Today?
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
On the date of publication, William White did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.